ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Investigation of V520 in an HIV Vaccine Proof-of-Concept Study

This study has been terminated.
Information provided by Merck

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Investigation of V520 in an HIV Vaccine Proof-of-Concept Study
Official Title 
Brief Summary

This study will test the safety and efficacy of V520 HIV vaccine. Efficacy will be measured by either prevention of HIV infection or control of HIV viral load in subjects who become HIV infected.

Detailed Description
Study Phase Phase II
Study Type  Interventional
Study Design  Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Primary Outcome Measure 
Secondary Outcome Measure 
Condition  AIDS
HIV Infections
Intervention  Biological: V520
MEDLINE PMIDs
Links Click here for more information about this trial This link exits the ClinicalTrials.gov site
Recruitment Information Fields
Recruitment Status  Terminated
Enrollment 
Start Date  December 2004
Completion Date
Eligibility Criteria 

Inclusion Criteria:

  • Healthy, HIV seronegative adults at high risk of acquiring HIV infection.
  • Cannot have previously received an investigational vaccine
Gender Both
Ages 18 Years to 45 Years
Accepts Healthy Volunteers Yes
Contacts ††
Location Countries 
Administrative Information Fields
NCT ID  NCT00095576
Organization ID 2004_091
Secondary IDs ††
Study Sponsor  Merck
Collaborators ††
Investigators 
Study Director:     Medical Monitor     Merck    
Information Provided By Merck
Verification Date September 2007
First Received Date  November 5, 2004
Last Updated Date September 26, 2007

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers